CD19 and B-cell non-Hodgkin lymphoma: Consistent with these results, Li et al. (20) reported that lymphoma cells were more sensitive to killing by CD19 CAR-T cells following pretreatment with DAC, and that two patients with refractory/relapsed B-cell lymphoma received sequential therapy (DAC followed by CAR-T cells), of whom both achieved CR.